CJC-1295 (No DAC) + Ipamorelin

Overview

It's completely reasonable — and intelligent — to be curious about CJC-1295 + Ipamorelin.

The CJC-1295 + Ipamorelin combination pairs a short-acting GHRH analog (CJC-1295 without the DAC moiety, typically called "Mod GRF 1-29") with a selective growth hormone secretagogue (Ipamorelin). Both act on the pituitary to induce endogenous GH release. Combined, they stimulate GH through two different upstream mechanisms, producing additive pharmacology in acute-dose studies.

The appeal is straightforward: many people researching this blend aren't chasing a "GH shortcut" — they want to understand how their own pituitary responds, preserve the pulsatile rhythm that physiologic GH release relies on, and support body composition goals alongside training and sleep.

The Science: Two Pathways, One Pituitary

Think of the GH axis as having two complementary "green lights" on the pituitary: GHRH receptors and ghrelin/GHS receptors. Pressing both at once produces a larger release than either alone — the pharmacologic basis for the combination.

• CJC-1295 (No DAC), aka Mod GRF 1-29 — A 29-amino-acid GHRH analog with a D-alanine substitution at position 2 for DPP-4 resistance. Unlike the DAC version, it retains a short half-life (~30 minutes), producing a pulsatile GH release pattern rather than sustained elevation. See the CJC-1295 profile for full background.
• Ipamorelin — A selective ghrelin-receptor agonist that induces GH release without elevating cortisol, prolactin, or ACTH at typical research doses. See the Ipamorelin profile for full background.

Rationale for the combination:

• Synergistic pituitary output. Published acute-dose studies describe additive or modestly synergistic GH release when GHRH and GHS agonists are co-administered.
• Preserved pulsatility. Because neither component extends half-life dramatically (unlike the long-acting CJC-1295 DAC), the resulting GH release pattern resembles physiologic pulses rather than continuous elevation.
• Preserved feedback control. Somatostatin feedback on the pituitary remains intact, which distinguishes this stack pharmacologically from exogenous recombinant GH.

What Researchers Have Observed

• Body composition research. Pulsatile GH stimulation is studied in contexts of muscle preservation, adipose reduction, and age-related GH decline, with the combination producing larger GH responses than single agents.
• GH axis physiology research. The combination is used as a research tool to probe GHRH-R and GHSR-1a pharmacology.
• Post-menopausal and adult GH insufficiency research. Academic interest in whether pulsatile stimulation provides a physiologic alternative to recombinant GH in select populations.
• Acute pharmacology. Well-characterized in healthy adults at the component level; the blend itself has less formal combined-dose research.

The Empowerment Angle: Quality of Life Research

Many people researching this combination aren't looking for a "GH replacement." They're exploring it as part of:

• Understanding their own endocrine system — how GH, IGF-1, sleep, and training interrelate
• Supporting body composition while preserving the rhythmic, pulsatile GH biology that physiologic signaling depends on
• Curiosity about age-related GH decline and whether stimulating endogenous release differs meaningfully from exogenous GH
• Taking an active role in healthspan rather than passively watching somatopause unfold
• Contributing to citizen science through careful documentation of training, sleep, body composition, and lab markers

The philosophy is informed self-experimentation — understanding why pulsatile GH biology matters helps you interpret what you observe.

State of the Evidence

Important context: Component-level acute pharmacology is well-characterized in healthy-adult studies.

• Long-term human outcome data specifically for the combination at sustained dosing are not published in peer-reviewed literature at the scale that would support efficacy claims for body composition or anti-aging endpoints
• Both components appear on the WADA Prohibited List — relevant for competitive athletes
• Neither component is FDA-approved
• Most real-world use is in self-experimentation and compounding-pharmacy contexts

This isn't an invalidation — it's an honest statement that component pharmacology is better studied than long-term combined-use outcomes. The stack remains a useful tool for learning about GH axis biology.

Approaching Research Responsibly

If you're considering researching this combination, the most empowered approach combines curiosity with rigor:

The most mature approach isn't blind optimism or reflexive skepticism, but curious, methodical, well-informed self-experimentation.

This entry was rewritten to help you understand both the science and the human motivation behind researching CJC-1295 + Ipamorelin. The goal is informed curiosity and empowerment, not medical advice.

References

1. [1]Teichman SL et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting analog of GHRH(2006) · doi:10.1210/jc.2005-1536
2. [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue(1998) · doi:10.1530/eje.0.1390552
3. [3]Bowers CY. GH releasing peptides — structure and kinetics(1998) · doi:10.1016/S0169-328X(98)00217-6